摘要
目的观察沙库巴曲缬沙坦治疗慢性心力衰竭(CHF)的临床效果。方法选取2018年2月至2019年7月在朝阳市中心医院心内科住院治疗的CHF患者120例为研究对象,随机分为对照组(n=60)及观察组(n=60)。对照组患者采用包括血管扩张剂、利尿剂、β受体阻滞剂、血管紧张素转化酶抑制剂(ACEI)或血管紧张素II受体阻滞剂(ARB)、醛固酮受体阻滞剂等常规抗心力衰竭治疗,并根据患者症状和体征及时调整治疗方案;观察组治疗将ACEI/ARB替换为沙库巴曲缬沙坦钠,起始剂量25 mg,2/d,根据患者血压情况,增加剂量至最大耐受剂量,两组患者均连续治疗6个月。比较两组临床疗效、超声心动图测定心功能指标左室射血分数(LVEF)、每博量(SV)、心输出量(CO)、左室短轴缩短率(FS);测定血清中炎症因子白介素1β(IL-1β)、白介素6(IL-6)、白介素18(IL-18)、白介素33(IL-33)、白介素37(IL-37)表达情况;记录治疗期间患者住院次数、住院时间,并统计不良反应发生情况。结果观察组总有效率为93.33%,高于对照组的73.33%(P<0.05)。治疗后,两组患者心功能指标(LVEF、SV、CO、FS)和炎症因子(IL-1β、IL-6、IL-18、IL-33、IL-37)均较治疗前明显改善(P<0.05),且观察组明显优于对照组(P<0.05)。两组不良反应发生率相近(P>0.05);与对照组相比,观察组患者住院次数及住院时间明显较少(P<0.05)。结论沙库巴曲缬沙坦钠治疗CHF患者安全有效,且可明显减轻患者机体炎症状态。
Objective To observe the clinical effect of sacubatro and Valsartan in the treatment of chronic heart failure(CHF).Methods 120 CHF patients hospitalized in the Department of Cardiology of Chaoyang Central Hospital from February 2018 to July 2019 were selected as the research objects and randomly divided into control group(n=60)and observation group(n=60).The control group was treated with conventional anti heart failure therapy including vasodilator,diuretic,β-blocker,angiotensin converting enzyme inhibitor(ACEI)or angiotensin II receptor blocker(ARB),aldosterone receptor blocker,etc.,and the treatment plan was adjusted in time according to the symptoms and signs of the patients;the observation group was treated with ACEI/ARB instead of sacubatre,valsartan sodium,starting agent The dosage was 25 mg/time,twice a day.According to the blood pressure of the patients,the dosage was increased to the maximum tolerated dose.Both groups were treated for 6 months.The clinical efficacy,left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO)and left ventricular short axis shortening rate(FS)were compared between the two groups;the expression of serum inflammatory factors IL-1β,IL-6,IL-18,IL-33 and IL-37 were measured;the treatment period was recorded The number of hospitalizations,length of stay,and the incidence of adverse reactions were analyzed.Results The total effective rate of the observation group was 93.33%,which was higher than 73.33%of the control group(P<0.05).After treatment,the cardiac function indexes(LVEF,SV,Co,FS)and inflammatory factors(IL-1β,IL-6,IL-18,IL-33,IL-37)of the two groups were significantly improved(P<0.05),and the observation group was significantly better than the control group(P<0.05).The incidence of adverse reactions in the two groups was similar(P>0.05);compared with the control group,the number and length of hospital stay in the observation group were significantly less(P<0.05).Conclusion Sacubitril/valsartan is effective and safe in treating chronic heart failure,a
作者
宋彩虹
周秋杰
张凤梅
陆峥
吴迪
Song Caihong;Zhou Qiujie;Zhang fengmei;Lu Zheng;Wu Di(Department of Cardiology,Chaoyang Central Hospital,Chaoyang 122000,China;不详)
出处
《中国循证心血管医学杂志》
2021年第1期105-108,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词
慢性心力衰竭
沙库巴曲缬沙坦钠
疗效
炎症
Chronic heart failure
Sacubitril/valsartan
Curative effect
Inflammation
